HUTCHMED to Present Promising Data on Multiple Cancer Treatments at ASCO 2025 Annual Meeting

HUTCHMED (HCM) will present data on its cancer therapies at the ASCO Annual Meeting in 2025, including Phase III SACHI study results showing savolitinib combined with osimertinib improved progression-free survival in advanced non-small cell lung cancer patients with MET amplification; early data on ranosidenib showed promising tolerability and efficacy in solid tumors with IDH mutations, though the objective response rate was only 7.1% in lower-grade glioma patients; and fruquintinib demonstrated manageable safety and meaningful clinical outcomes in advanced endometrial and colorectal cancer treatments, although Grade 3 or above treatment-emergent adverse events were noted.

Analysis

HUTCHMED (China) Limited is set to unveil new clinical data for its oncology portfolio at the ASCO Annual Meeting from May 30 to June 3, 2025, underscoring its research and development momentum. A key highlight includes late-breaking Phase III SACHI study results for savolitinib combined with osimertinib, which achieved its primary endpoint of improved progression-free survival (PFS) in advanced non-small cell lung cancer (NSCLC) patients with MET amplification; this data supports a New Drug Application (NDA) already granted priority review in China. Further supporting this combination, SAVANNAH Phase II data also demonstrated superior efficacy outcomes and promising central nervous system activity. Fruquintinib data will detail meaningful clinical outcomes in advanced endometrial cancer, with the FRUSICA-1 study showing an Independent Review Committee (IRC)-assessed objective response rate (ORR) of 37.0% and a disease control rate (DCR) of 88.9% in the serous carcinoma subgroup, alongside a manageable safety profile in colorectal cancer, though treatment-emergent adverse events (TEAEs) of Grade 3 or above were reported in 23.94% (monotherapy) and 26.06% (combination therapy) of patients in a Phase IV study. Conversely, while ranosidenib demonstrated favorable tolerability and a 100% DCR in a Phase I study of 14 lower-grade glioma patients, its ORR was a modest 7.1%, indicating potentially limited efficacy in this small cohort. Institutional sentiment reflects this mixed outlook, with 44 funds decreasing their HCM positions versus 19 increasing in Q1 2025; notable changes include UBS Group AG reducing its holding by 161,163 shares (-42.7%) and Millennium Management LLC by 99,058 shares (-47.3%), while Jane Street Group, LLC added 124,771 shares (+128.0%) and BlackRock, Inc. increased its stake by 57,707 shares (+369.9%). The company's prospects are heavily tied to positive outcomes from these studies, and the inherent uncertainty of forward-looking statements warrants careful consideration regarding future regulatory approvals and market acceptance.

Key Decisions for Investors

• Investors should closely scrutinize the detailed ASCO presentations, particularly for savolitinib's full SACHI and SAVANNAH data given its advanced regulatory status in China, and for further context on ranosidenib's efficacy beyond the initial 7.1% ORR in the small glioma cohort.
• A cautious approach is advisable due to the mixed clinical signals, such as the promising DCR but low ORR for ranosidenib, and the balance between fruquintinib's efficacy and its Grade 3 or higher TEAE rates, which could impact its risk-benefit profile.
• The divergent institutional investor activity, with significant net selling by number of funds but substantial new or increased stakes by others like Jane Street and BlackRock, suggests a period of valuation reassessment; therefore, a thorough evaluation of the risk/reward profile is crucial before making significant portfolio adjustments based on these upcoming data releases.